yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Today's Top SOA Links

Prima BioMed Releases Interim Immune Monitoring Data From CVac Clinical Trial
Interim Immune Monitoring Data Demonstrate Positive Effects of CVac(TM); Conference Call to Present the Data Scheduled for November 15th

SYDNEY, AUSTRALIA -- (Marketwire) -- 11/13/12 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") today released interim immune monitoring data from its ongoing CAN-003 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy.

The interim data demonstrate the positive effects of CVac treatment on the immune system.

The Company has completed intracellular cytokine staining ("ICS") analysis of seven patients from the CAN-003 trial -- five patients from the CVac group and two patients from the control group, who did not receive any cancer treatment during the study.

As compared to the control group, the CVac patients demonstrated much higher T cell activity throughout the testing period. ICS testing also indicates that the T cell response is specific to mucin 1, the antigen marker present on most ovarian cancer cells.

Prof. Ian Frazer, the chairman of Prima's scientific advisory board commented: "There is clear evidence of a cellular response to mucin 1 induced by CVac treatment. We look forward to further analysis of all patients on the CAN-003 study to see if these early trends are confirmed."

Matthew Lehman, Prima's CEO, stated: "We are encouraged by the interim trends we have seen in the CAN-003 data released to date. CVac has a very favourable side effect profile, the clinical data in terms of progression free survival are trending in the right direction, and the early ICS data support our hypothesis of how the product should work in a patient's body."

ICS is a laboratory technique used to evaluate if CVac has induced a desired mucin 1 specific T cell response in patients treated with CVac. The ICS results help confirm the biological activity of CVac.

Prima will make a presentation of the CAN-003 interim data via a conference call and webcast on Thursday November 15th at 9:00am (Sydney local time).

Conference call and webcast details:

Conference call dial-in numbers:

Australia Toll Free                1 800 131 617
Australia Alternate Toll Free      1 800 838 758
Canada/USA                         1 855 237 2970
Germany                            0800 189 9369

Webcast Link:

The webcast can be accessed via the following link;

Before launching the webcast, it is recommended to click on the link and then on "Test your systems configuration." A replay of the teleconference and webcast will be available through Prima's website following the live event.

About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

About CAN-003
CAN-003 is an open label, randomized, multinational, controlled phase 2 study. Sixty-three ovarian cancer patients in first or second remission have been enrolled. The first seven patients were not randomized and all received CVac. Subsequently, 29 patients were randomized to the CVac group compared to 27 patients in the observation standard of care group.

For further information please contact:
Australia Investor/Media
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact

USA Investor/Media:
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Ten short years ago, Apache Hadoop was just a small project deployed on a few machines at Yahoo and within a few years, it had truly become the backbone of Yahoo’s data infrastructure. Additionally, the current Apache Hadoop market is forecasted to surpass $16 billion by 2020. This mi...
COMED, my power company, sends out a monthly report that shows me my energy consumption relative to my neighbors. Every month I’m considerably higher than all my neighbors. This report also has a list of things I could do to reduce my energy consumption. The problem with this report is...
My favorite writer, Gil Press, sums it up with, “It’s Official: The Internet Of Things Takes Over Big Data As The Most Hyped Technology” where he talks about how Gartner released its latest Hype Cycle for Emerging Technologies, and how big data has moved down the “trough of disillusion...
When we talk about the impact of BYOD and BYOA and the Internet of Things, we often focus on the impact on data center architectures. That's because there will be an increasing need for authentication, for access control, for security, for application delivery as the number of potentia...
Last week, I was a keynote speaker at the Mobile Edge '16 conference in Lisbon, Portugal. Following the conference I met individually with many different companies. These companies represented a variety of industries, sizes and digital maturity levels. I was sharing my latest digital ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers